Prevalence and risk factors of hepatitis B and C viruses among haemodialysis patients in Gaza strip, Palestine by El-Ottol, Abed El-kader Y et al.
RESEARCH Open Access
Prevalence and risk factors of hepatitis B and C
viruses among haemodialysis patients in Gaza
strip, Palestine
Abed El-kader Y El-Ottol
1*, Abdelraouf A Elmanama
2, Basim M Ayesh
3
Abstract
Background: The prevalence of hepatitis B virus (HBV) and hepatitis C virus (HCV) and its associated risk factors
among haemodialysis (HD) patients in Gaza strip was investigated using serological and molecular techniques.
Results: The overall prevalence of HBV among the four HD centers was 8.1%. The main risk factors were HD center
(p = 0.05), history of blood transfusion (p < 0.01), and treatment abroad (p = 0.01). The overall prevalence of HCV
among the four HD centers was 22%. The main risk factors were HD center (p < 0.01), time duration on HD (p <
0.01), history of blood transfusion (p < 0.01), treatment abroad (p < 0.01), and history of blood transfusion abroad
(p < 0.01). Serum aminotransferases levels decreased in HD patients compared with normal population but still
there was a direct association between the activity of liver enzymes and both HBV (p < 0.01) and HCV (p < 0.01)
infection.
Conclusion: The much higher prevalence of Hepatitis viruses among HD patients compared to the normal
population of Gaza strip indicates a causative relation between HD and hepatitis viruses transmission. Therefore
extremely careful observation of preventive infection control measures is essential to limit Hepatitis viruses’
transmission in HD centers.
Introduction
Hepatitis B virus (HBV) and hepatitis C virus (HCV)
infections are important causes of morbidity and mortal-
ity among haemodialysis (HD) patients and pose pro-
blems in the management of patients in the renal dialysis
units, because chronic renal failure patients do not clear
these viral infections efficiently [1]. In Arab countries, the
prevalence of chronic HBsAg positivity among HD
patients ranged from 2% in Morocco, to 11.8% in Bahrain
[2-5]. Also In Arab countries the prevalence of HCV anti-
bodies among HD patients has been reported to range
from 27% in Lebanon to 75% in Syria [6-9].
However there are strong indications that studies of
HD patients which rely solely on serological screening
could underestimate the prevalence of HCV infection.
Partial immunesuppression in these patients, resulting in
poor antibody response may be a contributing factor
[10]. Such shortcomings could be overcome by deter-
m i n i n gH C VR N A ,w h i c hm a yb er e q u i r e dt oi d e n t i f y
all infected patients [11].
No documented data or previous studies have been
reported on the prevalence of hepatitis viruses among
HD patients in Palestine and to the best of our knowl-
edge this study is the first to address this issue. There-
fore the main objective of this study was to estimate the
prevalence of HBV and HCV among HD patients in
Gaza strip and address the major risk factors for trans-
mission of these viruses among HD patients.
Materials and methods
Patients
All of the four governmental HD centers of Gaza strip
were included in this study, and a total of 246 patients
were tested during August to September 2007. The
study principles and protocols were submitted and
approved by the committee of Helsinki, verbal consent
was obtained from each patient after the principle of the
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All personal information of the study subjects and
result were dealt with in confidentiality. A close ended
and multiple choice based questionnaire was completed
by the researcher via patient interview to ensure proper
data collection and prevent any misunderstanding.
Samples collection
Two blood samples were collected from each patient, in
plain tube, prior to dialysis to prevent the interference
of heparin with downstream applications. Serum from
the first tube was tested within two hours for ALT,
AST, HBsAg, and anti-HCV antibodies. Serum from the
second tube was frozen at -70°C in a sterile, DNAse,
R N A s ef r e et i g h t l yc a p p e dt u b eu n t i lu s e df o rP C R
analysis.
Virology
For HBsAg determination, Axsym HBsAg version 2.0 kit
(Abbott, USA) was used, Non reactive samples were
considered negative for HBsAg and not tested further,
while a reactive sample was retested to confirm the
result; a repeatedly reactive sample was considered posi-
tive and not further tested.
For anti-HCV antibodies determination, Axsym HCV
version 3.0 kit (Abbott, USA) was used. Non reactive
samples were considered negative for HCV, while reac-
tive samples were retested to confirm the result and
repeatedly reactive samples were considered positive.
Serologically positive HCV samples were tested indivi-
dually by nested RT-PCR technique, while negative sam-
ples were pooled in batches of ten and tested by the
same technique.
Chemistry
Serum alanine aminotransferase (ALT) and Serum
aspartate aminotransferase (AST) levels were analyzed
for all samples by using Diasys, (Germany) reagents, the
upper limit of normal for ALT and AST were set at 40
IU/ml and 37 IU/ml respectively [12].
Pooling of Serum Samples
A pooling strategy was developed and tested in this
study, in which ten serum samples from different
patients (negative anti-HCV) were pooled together in
one tube. Two hundred μl serum from each sample
were combined together in a single 2 ml microcentri-
fuge. The tubes were ultracentrifuged for two hours at
(21,000 × g) and cooling at 4°C. A pellet was visible and
the supernatant was reduced to approximately 150 μlb y
r e m o v a lo fm o s to ft h el i q u i d .T h ep e l l e tw a sr e s u s -
pended in the remaining serum and viral RNA was
extracted for PCR amplification. The samples of a
positive pool were either reanalyzed individually or sub-
divided into 3 smaller pools.
Molecular screening for HCV RNA
Viral RNA was extracted from serum samples using the
QIAamp viral RNA extraction kit according to the man-
ufacturer recommendation (Qiagen, Germany). Both
cDNA synthesis and PCR amplification of the target
s e q u e n c e sw e r ep e r f o r m e di nas i n g l et u b eu s i n gt h e
one step RT-PCR kit according to the manufacturer
instructions (Qiagen, Germany). The primers were
designed to specifically bind the 5′UTR of the HCV gen-
ome that is highly conserved among the different geno-
types. Primer sequences were as follows: sense external
primer (5′-CCCTGTGAGGAACTWCTGTCTTCA
CGC-3′); antisense external primer (5′-G GTGCACG
GTCTACGAGACCT-3′); sense internal primer (5′-
TCTAGCCATGGC GTTAG TRYGAGTGT-3′);a n d
antisense internal primer (5′-CACTCGCAAGCA
CCCTATCA GGCAGT-3′,W=Ao rT ,R =Ao rG ,
Y = T or C) [13].
The reactions were carried out in 25 μl volumes using
10 μlR N Ai nt h ep r e s e n c eo f0 . 6μMo fe a c hH C V
external primer, 400 μM of each dNTP and 5 units
RNase inhibitor. The reaction cycling conditions were: 1
cycle at 50°C for 30 minutes, 1 cycle at 95°C for 15 min-
utes followed by 40 cycles of 95°C for one minute, 55°C
for one minute and 72°C for one minute. Finally the
reactions were allowed to complete at 72°C for 10 min-
utes and held at 4°C.
In all cases a second nested PCR was performed to
improve the detection capacity and specificity of the
PCR test. The second PCR reactions were carried out in
25 μlv o l u m e su s i n g5μl DNA template from 1
st PCR
in the presence of 1× PCR master mix (Promega, USA)
and 0.4 μM of each HCV internal primers. The reaction
cycling conditions were 1 cycle at 95°C for 5 minutes,
followed by 34 cycles of 95°C for one minute, 55°C for
o n em i n u t ea n d7 2 ° Cf o ro n em i n u t e .F i n a l l yt h er e a c -
tions were allowed to complete at 72°C for 10 minutes
and hold at 4°C.
T h ep r o d u c t sw e r ea n a l y z e db y2 %a g a r o s eg e lw i t h
100 bp ladder and stained with ethidium bromide. The
appearance of a 298 bp and 235 bp bands was consid-
ered a positive results for the fist and the second PCR
respectively.
Statistical analysis
The data was collected, summarized, tabulated and ana-
lyzed using the statistical package for social sciences
(SPSS) V.13 software. Differences in proportions were
assessed by a chi-square test and mean comparisons by
the t-test, p-value < 0.05 was considered statistically
significant.
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During the study, 131 patients from Al-Shifa hospital in
the center of Gaza City, 30 patients from Shuhada’aA l -
Aqsa Hospital in Dair El-Balah, 52 patients from Nasser
hospital in Khan Yunis city, and 34 patients from Abu-
Yousef Al-Najar Hospital in Rafah city were included.
From the 246 patients tested, there were 131 male and
115 females. The Patients ages ranged from 6 to 80
years, and the mean age for all patients was 46.7 years
with standard deviation (SD) ± 17.5 years.
The overall prevalence of HBV among HD patients in
Gaza strip was found to be 8.1%. The highest percentage
was11.5% in Al-Shifa hospital, followed by 9.6% in Nas-
ser hospital, and no cases were detected in both Shuha-
da’a Al-Aqsa and Abu-Yousef Al-Najar Hospitals.
Analysis of risk factors showed that there was a highly
statistically significant relationship between HBV infec-
tion and age of the patient (p = 0.04). The mean age for
HBV positive patients was 39.2 ± 14.6 year, while for
HBV negative patients was 47.4 ± 17.6 year. Male
patients were found to be more susceptible to HBV
than female patients (p = 0.01) (Table 1).
Other risk factors with statistically significant relation
were, the HD center at which patients were treated (p =
0.05); the number of transfused blood units (p < 0.01);
and history of treatment Abroad (p = 0.01) (Table 2).
HBV was found to have a strong relationship with ALT
and AST levels. HBV positive patients had mean ALT
v a l u eo f2 2 . 4±2 0 . 9I U / m lw h i l en e g a t i v ep a t i e n t s
13.4 ± 11.8 IU/ml (p < 0.01); Also HBV positive patients
had AST mean value of 23.5 ±15.3 IU/ml while negative
HBV patients 15.2 ± 11.2 IU/ml (p < 0.01) (Table 3).
On the other hand, no statistically significant relation-
ship was found between HBV infection and the level of
education (p = 0.9); smoking (p = 0.51) (Table 1); HD
duration time (p = 0.68); blood transfusion abroad (p =
0.7); and surgical operation abroad ((p = 0.7 ) (Table 2).
The prevalence of anti-HCV was 17.9%. The highest
percentage was 26.7% in Al-Aqsa Hospital; followed by
23.1% in Nasser hospital, then 18.5% in Al-Shifa hospi-
tal, and 0% in Al-Najar Hospital (Table 4).The preva-
lence of HCV RNA was 19.1%. The highest percentage
was 36.7% in Al-Aqsa Hospital, then 23.1% in Nasser
hospital, 18.5% in Al-Shifa hospital, and 0% in Al-Najar
Hospital (Table 4).
By combining the results of both serological and
molecular methods, 22% of patients were found to be
HCV positive. 68.5% of the positive patient samples
were detected by the two methods, 18.5% of the positive
patient samples by nested RT-PCR method alone and
13% of the positive patient samples by serology method
alone (Table 4).
The highest prevalence of HCV was found at Al-Aqsa
Hospital (36.7%), followed by Nasser hospital (28.8%),
then Al-Shifa hospital (21.5%), and Al-Najar Hospital
(0%). Four cases (1.6%) were identified as positive for
both HBV and HCV, two cases at Al-Shifa center, and
the other two cases at Nasser hospital.
For HCV infection a highly statistically significant rela-
tionship was found between HCV infection and Education
level (p < 0.01). Most patients with HCV were found in
the preparatory level (40.7%) followed by the Elementary
level (20.4 %). Smoker patients appear to be more suscep-
tible to HCV than non smokers (p < 0.01) (Table 1).
Other risk factors for HCV include HD centers
(< 0.01), history of blood transfusion (p < 0.01), history
of treatment abroad (p < 0.01), blood transfusion abroad
(p < 0.01) and time duration on HD (p < 0.01). The









Age Mean Age 39.2 ± 14.6 47.4 ± 17.6 43.4 ± 15.5 47.6 ± 17.9
p Value 0.04 0.11
Patient Sex Male 16 (12.2%) 115 (87.8%) 30 (22.9%) 101 (77.1%)
Female 4 (34.8%) 111 (96.5%) 24 (20.9%) 91 (79.1%)
p Value 0.01 0.70
Education Level Illiterate 4 (6.2%) 61 (93.8%) 7 (10.8%) 58 (89.2%)
Elementary 4 (8.2%) 45 (91.8%) 11 (22.4%) 38 (77.6%)
Prep 6 (10.2%) 53 (89.8%) 22 (37.3%) 37 (62.7%)
Secondary 4 (7.8%) 47 (92.2%) 7 (13.7%) 44 (86.3%)
University 2 (9.1%) 20 (90.9%) 7 (31.8%) 15 (68.2%)
p value 0.9 < 0.01
Smoking Yes 2 (12.5%) 14 (87.5%) 8 (50%) 8 (50%)
No 18 (7.8%) 212 (92.1%) 46 (20%) 184 (80%)
p Value 0. 5 0.01
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30.3 ± 33.7 months while for positive HCV was 49.6 ±
42.4 month; (Table 2).
HCV also was found to have a strong relationship
with ALT and AST levels, Positive HCV patients have
mean ALT value of 19.9 ± 19.1 IU/ml while negative
HCV patients has ALT mean value of 12.53 ± 10.3 IU/
ml (p < 0.01). Also positive HCV patients had AST
mean value of 22.9 ± 16.9 IU/ml while negative HCV
patients has AST mean value of 13.9 ± 9.00 IU/ml
(p < 0.01) (Table 3).
No statistically significant relationship was found
between HCV and patient sex (p = 0.70) and age (p =
0.11) (Table 1), and surgical operation abroad (p-0.95)
(Table 2).
Discussion
Viral hepatitis remains a major hazard for both
patients and medical staff of HD units [14]. In this
study, the overall prevalence of HBV in HD patients in
Gaza strip was 8.1%. This prevalence higher than in
other neighboring countries like Jordan (5.9%) and
lower than others such as Saudi Arabia (10%) and Bah-
rain (11.8%) [3-5].
Statistically significant differences in prevalence
between the four HD centers are obvious (p = 0.05).
Such a result was also observed in a previously pub-
lished research in Jordan [3]. This difference in preva-
l e n c em a yb ed u et ov a r i a t i o ni nt h ed e g r e eo f
implementation of the universal precautions to prevent
nosocomial transmission.









HD Center Al-Shifa 15 (11.5) 115 (88.5) 28 (21.5) 102 (78.5)
Al-Aqsa 0 (0) 30 (100) 11(36.7) 19 (63.3)
Nasser 5 (9.6) 47 (90.4) 15(28.8) 37 (71.2)
Al-Najar 0 (0) 34 (100) 0 (0) 34 (100)
p Value 0.05 < 0.01
Time Duration on HD (month) Mean Time 37.7 34.3 49.6 30.3
p value 0.68 < 0.01
Number of Blood Units Transfused 0 7 (6.8) 96 (93.2) 19 (18.4) 84 (81.6)
1- 5 4 (6.7) 56 (93.3) 6 (10) 54 (90)
5-10 2 (4.4) 43 (95.6) 9 (20) 36 (80)
10-15 1 (5) 19 (95) 10 (50) 10 (50)
< 15 6 (33.3) 12(66.7) 10 (55.6) 8 (44.4)
p value < 0.01 < 0.01
Number of Patients Treated Abroad Yes 18 (11.8) 134 (88.2) 45 (29.6) 107 (70.4)
No 2 (2.1) 92 (97.8) 9 (9.6) 85 (90.4)
p value 0.01 < 0.01
Surgical Operation Abroad from the152 patients treated abroad yes 14 (11.5) 108 (88.5) 36 (29.5) 86 (70.5)
no 4 (13.3) 26 (86.7) 9 (30) 21 (70)
p value 0.7 0.95
Blood Transfusion Abroad from the 152 patients treated abroad yes 9 (12.9) 61 (87.1) 29 (41.4) 41 (58.6)
no 9 (11) 73 (89) 16 (19.5) 66 (80.5)
p value 0.70 < 0.01
Table 3 Relationship between HBV, HCV infection and liver enzymes among HD patients
Liver Enzymes HBV Positive HBV Negative HCV Positive HCV Negative
ALT mean 22.4 13.4 19.9 12.5
p Value < 0.01 < 0.01
AST mean 23.5 15.2 22.9 13.9
p Value < 0.01 < 0.01
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w a sf o u n db e t w e e nH B Va n dd u r a t i o no nH D ,t h i s
observation was in agreement with a previous report in
Moldavia [15], and in disagreement with another in Jor-
dan [3] In our study, the prevalence of HBV was
increased significantly with increasing the number of
blood units transfused (p < 0.01), This is in agreement
with a previous study in Brazil [16], while another study
in Jordan showed no relationship [3].
In general, most patients of Gaza strip with chronic
diseases or who are in need for major surgeries are trea-
ted abroad. Also some patients during their treatment
undergo HD. We found a statistically significant rela-
tionship between treatment abroad and HBV infection
(p = 0.01). A previous study in India showed that travel-
ing abroad is associated with increased risk of hepatitis
virus infection and this risk is expected to be increased
when traveling to endemic areas [17].
No statistically significant relationship was found
between HBV prevalence and surgical operation or
blood transfusion abroad. This result contradicts results
from a previous work in Brazil that showed that surgery
is a risk factor for acquiring hepatitis infection in the
general population [18]. This contradiction may be due
to differences in the type of surgery, the level of medical
services and other factors related to the countries were
surgeries are performed.
A statistically significant relationship was found
between HBV infection and age of the patients, as
patients less than 40 years old were found more suscep-
tible to HBV than older patients. This is in agreement
with a study done in Gaza among the general popula-
tion, which found that the highest percentage of HBsAg
among age group of 30 to 39 years [19]. The results also
showed that male HD patients had higher HBV preva-
lence than females. This may be related to the fact that
males in Palestine are more socially active than female.
Furthermore, they are more exposed to male-related
risk factors for HBV than female (e.g. hairdressing and
circumcision). This result is in agreement with study in
general population of Lebnon [20].
The prevalence of anti-HCV among HD patients was
17.9%, This anti-HCV prevalence was lower than Tuni-
sia (19.1%), Lebanon (27%), Jordan (34.6%), and Syria
(75%) [21,6,7,9]. Partial immunosuppression in HD
patients resulting in a poor antibody response to Hepati-
tis viruses’ infection [10] makes serological screening of
HCV underestimate. Such short coming could be over-
come by detecting HCV RNA [11].
In this study HCV RNA was detected in 19.1% of HD
patients, this result is lower than some countries such as
Brazil (30.6%) and Greece (31.7%) [22,23]. HCV RNA
was detected in only 84.1% of the anti-HCV positive
patients. This deviation between PCR and ELISA results
was also previously reported in many studies like in Syria
(87.5%), Jordan (30.6%), and Tunisia (72.3%) [9,7,16]. The
possible explanations for this Difference in percentage of
viraemic patients includes false positive serology, inter-
mittent viraemia, or the level of viraemia in is below the
lower limit of PCR detection [7]. Also the viral load is
relatively low in this group of patients and long term
maintenance HD decreases the HCV RNA level but
doesn’t produce clearance of viraemia [24].
On the other hand, HCV RNA was detected in serum
of 10 patients of the anti-HCV negative (4.95%). Again,
several studies have shown that serological assays alone
are not sufficient for diagnosis of HCV infection and the
detection of HCV RNA is required to identify all
infected patients [25]. So detection of HCV RNA is
more reliable than serology in detecting ongoing HCV
infection in HD patients who may not mount an ade-
q u a t ea n t i b o d yr e s p o n s e[ 2 5 ] .O u rr e s u l t sa m o n gs e r o -
negative patients were higher than studies in center of
Recife, Brazil (0%) [26], but lower than another study in
central Brazil (10.3%) [27]. The overall prevalence of
HCV among Gazian HD patients thus is (22 %). This is
higher than in Germany in which the overall prevalence
was (3%) [28] and lower than in Brazil (46.7%) [29].
HCV prevalence was different between HD centers,
and as stated earlier, this difference in prevalence may
be due to different degrees of commitment to universal
precautions taken in each center, the same result was
shown in previous studies in Jordan and Tunisia [7,21].
Duration on HD was found to be a statistically signifi-
cant risk factor for HCV infection in HD setting. The
risk of HCV infection increased with increasing the time
duration. In HD population under investigation, other
studies from different regions in the world have shown
similar results [30].
This effect may be due to nosocomial transmission of
HCV as indicated by other studies, epidemiological and
molecular studies have shown the role of HD environ-
ment for dissemination of HCV between patients
[31,32]. Actually in our study it was not unusual to find
staff taking care of susceptible and infected patients in
the same shift. Additionally they didn’t routinely discard
gloves after use; this practice may facilitate the dissemi-
nation of HCV RNA between HD patients.







anti- HCV positive 37 (15%) 7 (2.8%) 44 (17.9%)
anti- HCV
negative
10 (4.1%) 192 (78%) 202
(82.1%)
Total 47 (19.1%) 199 (80.9%) 246 (100%)
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significant risk factor in this study. The risk increased
with the increase in the number of blood units which
were transfused (p < 0.01). This result was in agreement
with other study in USA[33].
No relationship was found between HCV prevalence
and sex of the patients, this was in agreement with other
studies [34]. Also no statistically significant relationship
was found between HCV prevalence and patient’sa g e ;
this finding is supported by other study [34].
A direct statistically significant relationship was found
between HCV and education level in which most of
HCV positive patients were in the preparatory level fol-
lowed by elementary. Previous studies among general
population worldwide showed that HCV is prevalent
among less educated level people [35].
In this study a direct relationship was found between
HCV prevalence and smoking, in which smoker patients
are more susceptible to HCV than non smokers. This
may be due to bad practices in Gaza strip where people
are smoking water pipe (Shisha) in groups. Water pipe
is passed from one person to another; the mouth piece
maybe wiped but is not changed between users, which
theoretically result in exposure to blood from indivi-
duals with gingivitis for example; Also smokers are
highly associated with increased visit to outpatient phy-
sician and hospital services, a result that was indicated
in reports among general population.
The striking difference in prevalence and risk factors
seen between HBV and HCV, with similar molecular
size and transmission routes in general and the HD
population, was also described by others [36].
Co-infection with both HBV and HCV was reported
in 4 patients (1.6%) of the total HD population which is
low when compared with other study in Moldavia [15].
In our study a direct and strong association between
the activity of liver enzymes and both HBV and HCV
prevalence was found. Previous studies suggested that
ALT levels, even that not exceeding upper limit of nor-
mal are higher in anti-HCV positive patients in compar-
ison with anti-HCV negative patients [37,38]. Therefore
recriteria for normal reference of ALT and AST is pro-
posed for HD population. On the other hand, other
study suggested that serum aminotransferases aren’t reli-
able marker for HCV screening or for evaluation of
hepatitis activity in HD patients since they are fre-
quently normal [39].
Conclusion
Hepatitis B and C viruses’ infection are very frequent
among HD patients in Gaza strip as in many regions of
the world. The HD center, blood transfusion and treat-
ment abroad appear to be the major risk factors for
both viruses.
For HBV infection other risk factors included, younger
age and male patients. Further studies among total
population are needed to investigate this factor. For
HCV other risk factors for infection include, the dura-
tion on HD, smoking, and the level of education.
The much higher prevalence of Hepatitis viruses
among HD patients compared to the normal population
of Gaza strip indicates a causative relation between HD
and hepatitis viruses transmission.
Therefore extremely careful observation of preventive
infection control measures is essential to limit Hepatitis
viruses’ transmission in HD centers.
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